Transformation and Metastasis

Eva Gonzalez Suarez

CLINICAL RESEARCHERS
  • Maria Teresa Soler Monsó
  • Andrea Carolina Vethencourt Casado
POSTDOCTORAL RESEARCHERS (R2)
  • Eva Maria Trinidad Alvarez
  • Ana Sofia Semiao Da Rocha
  • Juliana Carvalho Santos
  • Kim Vagn Bollingeoft Pedersen
  • Enrique Hernández Jiménez
PREDOCTORAL RESEARCHERS (R1)
  • Alexandra Barranco López
  • Clara Gomez Aleza
  • Sandra Benitez Sorribas
  • Marina Ciscar Garcia
  • Alejandro Collado Solé
SCIENTIFIC SUPPORT
  • Manuel Gris Lorente
CANCER
Cancer Epigenetics and Biology

Scientific production

7

PAPERS

4 PUBLICATIONS IN FIRST DECILE

5 PUBLICATIONS IN FIRST QUARTILE

Selected publications

  • Gómez-Miragaya J, Díaz-Navarro A, Tonda R, Beltran S, Palomero L, Palafox M, Dobrolecki LE, Huang C, Vasaikar S, Zhang B, Wulf GM, Collado-Sole A, Trinidad EM, Muñoz P, Paré L, Prat A, Bruna A, Caldas C, Arribas J, Soler-Monso MT, Petit A, Balmaña J, Cruz C, Serra V, Pujana MA, Lewis MT, Puente XS, González-Suárez E . Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.. CANCER RESEARCH. 10.1158/0008-5472.CAN-18-3835
  • von Moos R., Costa L., Gonzalez-Suarez E., Terpos E., Niepel D., Body J.J.. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. CANCER TREATMENT REVIEWS. 10.1016/j.ctrv.2019.05.003
  • Gómez-Miragaya J, Morán S, Calleja-Cervantes ME, Collado-Sole A, Paré L, Gómez A, Serra V, Dobrolecki LE, Lewis MT, Diaz-Lagares A, Eroles P, Prat A, Esteller M, González-Suárez E . The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.. MOLECULAR CANCER RESEARCH. 10.1158/1541-7786.MCR-19-0040

Research highlights

PROJECTS

12 Ongoing projects
5 Started projects 

1 Ongoing clinical trial

Selected projectes

  • RANK and LGR4 in mammary cell fate (1/4/2019 – 31/3/2022) PI: GONZALEZ SUAREZ, EVA. Funder: AGAUR-GENERAL.CATALUNYA.
  • RANK, instead of RANKL, as a new therapeutic target in Triple Negative Breast Cancer (1/9/2019 – 31/8/2021) PI: GONZALEZ SUAREZ, EVA. Funder: ASOCIACION ESPAÑOLA CONTRA EL CANCER.
  • PLEIO-RANK:Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity (1/10/2016 – 30/9/2021) PI: GONZALEZ SUAREZ, EVA. Funder: COMUNITAT EUROPEA.
  • Nuevos avances en el estudio de la vía de RANK en cáncer de mama: de la biología al tratamiento (1/1/2018 – 31/12/2020) PI: GONZALEZ SUAREZ, EVA. Funder: MINISTERIO DE EDUCACION Y CIENCIA.
  • Nuevas dianas terapéuticas en cáncer epitelial New therapeutic targets in epithelial tumors (1/1/2018 – 31/12/2020) PI: GONZALEZ SUAREZ, EVA. Funder: AGAUR-GENERAL.CATALUNYA.
  • An open label biomarker pilot study of the antitumoral activity of denosumab in the pre- operative setting of early breast cancer (26/1/2017 – 26/1/2019) PI: GONZALEZ SUAREZ, EVA. Funder ref.: 20119112.
  • Biomarker identification after RANKL inhibition using patient derived breast cancer orthoxenografts (8/11/2016 – 9/11/2020) PI: GONZALEZ SUAREZ, EVA. Funder ref.: Study 20167353.